Project Grant DP5OD037346
Award Date
9/18/24
Completion Date
7/31/29
Dollars Obligated
$406K
Funding Federal Agency
Office of the Director
Awarding Federal Agency
Aggregate Financial Assistance Data
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $239,991 to The Trustees of the University of Pennsylvania to conduct research aimed at deciphering and modulating chimeric antigen receptor (CAR) T cell persistence and overcoming CAR T cell exhaustion. The key products and services to be delivered under this award include: Development of novel split-engineered CRISPR/dCAS9-guided epigenome editors that can inducibly activate target...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $604,627 to the Trustees of Dartmouth College to conduct research aimed at deconvoluting the heterogeneity of chimeric antigen receptor (CAR) T cells in order to engineer durable antitumor immunity. The research project, which runs from January 1, 2025 to December 31, 2029, will use dynamic lineage recording to understand how individual CAR T cell subsets behave in vivo and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Trustees of the University of Pennsylvania is focused on engineering a protein therapeutic to limit the transformation of the patient's own anti-tumor autoantibodies into highly potent T cell-redirecting antibodies, specifically within the tumor microenvironment. The $216,682 award, effective March 1, 2025 through February 28, 2027, aims to optimize the engineered protein therapeutic...
The University of Pittsburgh was awarded a $1,271,780 Project Grant by the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), to develop small molecule adaptors for precision control of universal chimeric antigen receptor (CAR) T cell therapy. The project aims to: 1) create small molecule adaptors for targeting universal CARs to multiple antigens, including tumor cells and immunosuppressive cells; 2) enhance CAR targeting specificity using chemical...
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,602,000.00 to The Children's Hospital of Philadelphia Research Institute to develop and optimize a new class of Epigenetic Reprogramming Factors (ERFs) that can target hundreds, thousands, or tens of thousands of DNA regions in a pathway-specific manner. The goal is to leverage this ERF technology to prevent or reverse epigenetic signatures associated...
This Cooperative Agreement, awarded by the National Cancer Institute (NCI) under CFDA Program 93.394 - Cancer Detection and Diagnosis Research, provides $1,453,091 in funding to develop and clinically evaluate an imaging-enabled, adaptable CAR T cell (IMAC) therapy platform. The University of Pennsylvania will lead this project, which aims to create a novel CAR T cell approach that can be monitored and controlled through PET imaging and targeted biologics. The goal is to enable safe and...
The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $627,272 project grant to The Johns Hopkins University on Feb 24, 2025 to develop and optimize engineered, self-propelled tumor-infiltrating CAR T cells using synthetic cytokine receptors (velocity receptors) to enhance their migration speed and tumor infiltration capabilities. The goal is to improve the efficacy of CAR T cell therapy for treating pancreatic cancer, which has a 5-year survival rate of just ~12%....
This $107,948 Project Grant awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) will fund the development of tunable, microenvironment-responsive CAR T cells to enhance the potency and safety of solid tumor CAR T cell therapy, with a focus on ovarian cancer. The research aims to engineer a hypoxia biosensor circuit in primary human T cells to enable targeted CAR expression and cytokine delivery within the tumor microenvironment, thereby improving anti-tumor efficacy...